In today's world, Adrenal crisis is a topic that has captured the attention of many people in different areas of society. From its impact on the economy to its influence on popular culture, Adrenal crisis has become a topic of great relevance today. With the advancement of technology and constant changes in society, it is crucial to understand and analyze how Adrenal crisis is affecting our lives. In this article, we will explore different aspects of Adrenal crisis and its impact on our world, from its origins to its relevance today.
The biggest trigger for adrenal crisis is gastrointestinal illness. The physiological mechanisms underlying an adrenal crisis involve the loss of endogenous glucocorticoids' typical inhibitory effect on inflammatory cytokines.
A tailored prescription, as well as a strategy for administering additional glucocorticoids for physiological stress, are critical preventative measures. When an adult experiences an adrenal crisis, they require immediate parenteral hydrocortisone.
About 6 to 8% of patients with adrenal insufficiency experience an adrenal crisis at some point each year. The mortality rate linked to adrenal crises is up to 6%.
There is a greater risk for adrenal suppression with longer durations, greater doses, and oral and intraarticular preparations. Nonetheless, no amount, time frame, or mode of administration can reliably predict adrenal insufficiency.
Patients with adrenal insufficiency have a 50% lifetime risk of experiencing an adrenal crisis, and those who have experienced an adrenal crisis in the past seem to be more susceptible to another episode.
Triggers
A known precipitating event can be found in over 90% of episodes of adrenal crisis. The most common cause of adrenal crisis is gastrointestinal illness. This is probably because it has a direct impact on how well oral glucocorticoids are absorbed through the intestines. Stress from surgery is another common cause.
Loss of cortisol suppresses nuclear factor κB (NF-κB) and activator protein 1 (AP-1) at the cellular level, which allows genes that generate inflammatory proteins to be activated without restriction. This is because cortisol normally inhibits NF-κB's binding to the glucocorticoid receptor. Additionally, through potassium retention and sodium and water loss, mineralocorticoid deficiency—which is common in primary but not in secondary adrenal insufficiency—is likely to aggravate adrenal crises.
Diagnosis
When a patient with adrenal insufficiency is known to be exhibiting symptoms of an adrenal crisis, treatment needs to start right away. When a patient is deemed medically unstable, treatment shouldn't be postponed in even when diagnosis is still pending.
Adrenal insufficiency can be diagnosed with renin, dehydroepiandrosterone sulfate, aldosterone, serum cortisol, and ACTH levels which can be taken right before hydrocortisone is administered. A high cortisol level of more than 20 mg/dL (550 nmol/L) can rule out the diagnosis. A low cortisol level of less than 5 mg/dL (138 nmol/L), obtained in the early morning or during a stressful period, strongly suggests the possibility of adrenal insufficiency. In instances of primary adrenal insufficiency, there is a correspondingly high ACTH level; in contrast, low or inappropriately normal ACTH correlates with tertiary or secondary adrenal insufficiency.
A customized prescription as well as a plan for the administration of additional glucocorticoids for physiological stress are important preventative measures. If oral glucocorticoids are not an option, parenteral hydrocortisone should be used, preferably at home. Devices like MedicAlert bracelets and necklaces can alert caregivers to the possibility of adrenal crisis in patients who are unable to communicate verbally.
Although the exact dosage has been debated, it is generally agreed upon that all patients with proven adrenal insufficiency should receive glucocorticoid replacement during stressful times. The recommended amounts of glucocorticoid replacement are dependent on the anticipated stress, and the current guidelines depend on expert opinion. Though there may be variations in specific regimens, most agree that stress doses for simple surgery should be quickly tapered and should not last longer than three days. This is because unneeded steroid excess can lead to infections, poor wound healing, and hyperglycemia.
In those who are unable to tolerate oral medication or do not respond to stress doses, a low threshold to initiate parenteral hydrocortisone management should be used to guarantee adequate systemic absorption, since gastroenteritis frequently precedes an adrenal crisis and a rise in oral glucocorticoids may not always avoid an adrenal crisis.
Patients experiencing vomiting, chronic diarrhea, or an imminent adrenal crisis should receive intramuscular hydrocortisone. Patients must be prepared to administer it themselves because they can rapidly deteriorate. A lot of patients may own a hydrocortisone ampoule, but not all have practiced the injection, and most will depend on medical professionals to give it to them in the event of an adrenal crisis episode. Patients may experience significant physical as well as cognitive impairment during their illness, which may impair their capacity to make wise decisions or administer medicine. Therefore, patients should receive training on intramuscular hydrocortisone use and education on how to recognize an adrenal crisis, as well as assistance from a close family member or friend.
In case an individual suffering from adrenal insufficiency loses consciousness, they must receive the necessary medical attention. Reminding patients to always wear or keep a MedicAlert bracelet or just an emergency card is important. A survey of 46 patients revealed that some medical professionals are reluctant to medicate the condition even when it is brought to their attention, which is a serious cause for concern. Only 54% of patients got glucocorticoid administration within 30 minutes of arrival, even though 86% of patients were promptly attended to by a medical professional within forty-five minutes of a distress call. In situations when doctors are unsure about a patient's need for additional hydrocortisone, it is wise to listen to patients and their loved ones as they frequently have the most knowledge about this rare disorder.
Treatment
The two foundations of treatment for adrenal crisis are steroid replacement and fluid resuscitation. When adrenal crisis treatment is started as soon as possible, it can be effective in preventing irreversible effects from prolonged hypotension. Treatment shouldn't be postponed while doing diagnostic tests. If there is reason to suspect something, a blood sample could be taken right away for ACTH and serum cortisol testing; however, treatment needs to begin right away, regardless of the results of the assay. Once a patient has recovered clinically, it is safe to confirm the diagnosis in an acutely ill patient.
In cases of emergency, parenteral hydrocortisone can be given as soon as possible by intramuscular (IM) injection while IV access is being established, or as a bolus injection of 100 mg of intravenous (IV) hydrocortisone. After this bolus, 200 mg of hydrocortisone should be administered every 24 hours, either continuously by IV infusion or, if that is not possible, in doses of 50 mg of hydrocortisone per IV/IM injection every 6 hours. A constant infusion of hydrocortisone results in a cortisol concentration insert at a steady state.
Patients with hypoadrenalism are more likely to die from adrenal crises; the death rate from adrenal crises can amount to 6% of crisis events. "Adrenal failure" accounted for 15% of deaths in a study conducted in Norway involving 130 Addison's disease patients, making it the second most common cause of death. While symptoms may have gone unnoticed prior to the fatal episode, fatal adrenal crises have happened in patients who had never been diagnosed with hypoadrenalism.
Epidemiology
An adrenal crisis occurs in roughly 6–8% of those with adrenal insufficiency annually. Patients with primary hypoadrenalism experience adrenal crises somewhat more frequently compared to those with secondary adrenal insufficiency. This is likely due to the fact that patients with primary hypoadrenalism lack mineralocorticoid secretion and some secondary adrenal insufficiency patients retain some cortisol secretion. Despite varying degrees of consequent adrenal suppression, patients with hypoadrenalism from long-term glucocorticoid therapy rarely experience adrenal crises.
The treatment of pituitary tumors and the widespread use of opioids for both malignant and increasingly non-malignant pain, as well as exogenous glucocorticoid therapy for the numerous inflammatory as well as malignant conditions that become more common in people over 60, are the main causes of a new diagnosis of adrenal insufficiency in older adults. Adrenal crisis is more likely to occur in older people.Urinary tract infections, particularly in older women, are often linked to an adrenal crisis, as is pneumonia as well as a flare-up of chronic respiratory disease.Cellulitis is linked to adrenal crises within this age range and may be more prevalent in patients with fragile skin who have been exposed to higher doses of glucocorticoids. Older adults frequently experience falls and fractures, which may be linked to postural hypotension, especially in those who have primary adrenal insufficiency.
Older patients have a higher mortality rate from adrenal crisis, at least in part due to the existence of comorbidities that make treatment more difficult.
While studies on the prevalence of adrenal crisis in older adults are scarce, one population-based investigation into hospital admissions for adrenal crisis found that the incidence increased with age in older patients, going from 24·3 (60–69 years) to 35·2 (70–79 years) and 45·8 (80+ years) per million per year. This is significantly higher compared to the general adult admission rate, which is 15·0 per million annually in the same population.
Untreated adrenal crisis can cause severe morbidity in both the mother and the fetus, such as inadequate wound healing, infection, venous thromboembolism, extended hospital stays, preterm birth, fetal intrauterine growth restriction, and an increased risk of cesarean delivery. The occurrence of adrenal crisis during pregnancy is uncommon, even in patients who have a documented history of adrenal insufficiency. In one study, pregnancy was identified as a trigger for adrenal crisis in 0.2% of the 423 patients. In a different study only 1.1% of the 93 patients in the study who had a known insufficiency experienced an adrenal crisis during pregnancy.
Studies have demonstrated that younger children with congenital adrenal hyperplasia experience adrenal crisis events more frequently than older children and adolescents. Furthermore, research on congenital adrenal hyperplasia in children shows that individuals with more severe salt-wasting types have a higher chance of needing to be hospitalized. There are differences in the incidence of adrenal crises between the sexes, and these differences change with age. Psychosocial factors have the potential to alter the baseline adrenal crisis risk as well, especially as patients transition from parental treatment oversight to self-management in adolescence. Management in this age group is further complicated by changes in cortisol pharmacokinetics, resulting in an increased clearance as well as volume without a change to the cortisol half-life that has been shown during the pubertal period.
There is still a significant morbidity and death associated with adrenal insufficiency in newborns and early children. It has been estimated that 5–10 episodes of adrenal crisis occur for every 100 patient years in children with adrenal insufficiency; incidences may be higher in specific countries. Adrenal crisis among kids results in death in about 1/200 cases.
^ abcdBouillon R (December 2006). "Acute adrenal insufficiency". Endocrinology and Metabolism Clinics of North America. 35 (4). Elsevier BV: 767–75, ix. doi:10.1016/j.ecl.2006.09.004. PMID17127145.
^ abcOelkers W (October 1996). "Adrenal insufficiency". The New England Journal of Medicine. 335 (16). Massachusetts Medical Society: 1206–1212. doi:10.1056/nejm199610173351607. PMID8815944.
^Zelissen PM (1994). "Addison patients in the Netherlands: medical report of the survey". The Hague: Dutch Addison Society.
^Allolio B, Ehses W, Steffen HM, Müller R (June 1994). "Reduced lymphocyte beta 2-adrenoceptor density and impaired diastolic left ventricular function in patients with glucocorticoid deficiency". Clinical Endocrinology. 40 (6): 769–775. doi:10.1111/j.1365-2265.1994.tb02511.x. PMID8033368. S2CID695195.
^Johnston PC, Lansang MC, Chatterjee S, Kennedy L (March 2015). "Intra-articular glucocorticoid injections and their effect on hypothalamic-pituitary-adrenal (HPA)-axis function". Endocrine. 48 (2). Springer Science and Business Media LLC: 410–416. doi:10.1007/s12020-014-0409-5. PMID25182149. S2CID207363039.
^Habib G, Jabbour A, Artul S, Hakim G (January 2014). "Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic-pituitary-adrenal axis: a randomized controlled study". Clinical Rheumatology. 33 (1). Springer Science and Business Media LLC: 99–103. doi:10.1007/s10067-013-2374-4. PMID23982564. S2CID31438068.
^Levin C, Maibach HI (2002). "Topical corticosteroid-induced adrenocortical insufficiency: clinical implications". American Journal of Clinical Dermatology. 3 (3). Springer Science and Business Media LLC: 141–147. doi:10.2165/00128071-200203030-00001. PMID11978135. S2CID58051887.
^Hopkins RL, Leinung MC (June 2005). "Exogenous Cushing's syndrome and glucocorticoid withdrawal". Endocrinology and Metabolism Clinics of North America. 34 (2). Elsevier BV: 371–84, ix. doi:10.1016/j.ecl.2005.01.013. PMID15850848.
^St Clair K, Maguire JD (May 2012). "Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency". International Journal of STD & AIDS. 23 (5): 371–372. doi:10.1258/ijsa.2009.009339. PMID22648897. S2CID2193364.
^Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN (January 2004). "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole". The Annals of Pharmacotherapy. 38 (1). SAGE Publications: 46–49. doi:10.1345/aph.1d222. PMID14742792. S2CID24050351.
^ abcHahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, et al. (March 2010). "Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies". European Journal of Endocrinology. 162 (3). Oxford University Press (OUP): 597–602. doi:10.1530/eje-09-0884. PMID19955259. S2CID35229693.
^ abcWhite K, Arlt W (January 2010). "Adrenal crisis in treated Addison's disease: a predictable but under-managed event". European Journal of Endocrinology. 162 (1). Oxford University Press (OUP): 115–120. doi:10.1530/eje-09-0559. PMID19776201.
^Graves L, Klein RM, Walling AD (August 2003). "Addisonian crisis precipitated by thyroxine therapy: a complication of type 2 autoimmune polyglandular syndrome". Southern Medical Journal. 96 (8). Southern Medical Association: 824–827. doi:10.1097/01.smj.0000056647.58668.cd. PMID14515930. S2CID46328960.
^Bornstein SR (May 2009). "Predisposing factors for adrenal insufficiency". The New England Journal of Medicine. 360 (22). Massachusetts Medical Society: 2328–2339. doi:10.1056/nejmra0804635. PMID19474430.
^Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B (April 2015). "Timelines in the management of adrenal crisis — targets, limits and reality". Clinical Endocrinology. 82 (4): 497–502. doi:10.1111/cen.12609. PMID25200922. S2CID25790150.
^Sævik, Å. B.; Åkerman, A.-K.; Grønning, K.; Nermoen, I.; Valland, S. F.; Finnes, T. E.; Isaksson, M.; Dahlqvist, P.; Bergthorsdottir, R.; Ekwall, O.; Skov, J.; Nedrebø, B. G.; Hulting, A.-L.; Wahlberg, J.; Svartberg, J.; Höybye, C.; Bleskestad, I. H.; Jørgensen, A. P.; Kämpe, O.; Øksnes, M.; Bensing, S.; Husebye, E. S. (November 3, 2017). "Clues for early detection of autoimmune Addison's disease – myths and realities". Journal of Internal Medicine. 283 (2). Wiley: 190–199. doi:10.1111/joim.12699. ISSN0954-6820. PMID29098731.
^Smans, Lisanne C.C.J.; Van der Valk, Eline S.; Hermus, Ad R.M.M.; Zelissen, Pierre M.J. (August 27, 2015). "Incidence of adrenal crisis in patients with adrenal insufficiency". Clinical Endocrinology. 84 (1). Wiley: 17–22. doi:10.1111/cen.12865. ISSN0300-0664. PMID26208266. S2CID34814447.
^ abRushworth, R. Louise; Chrisp, Georgina L.; Torpy, David J. (2018). "Glucocorticoid-Induced Adrenal Insufficiency: A Study of the Incidence in Hospital Patients and A Review of Peri-Operative Management". Endocrine Practice. 24 (5). Elsevier BV: 437–445. doi:10.4158/ep-2017-0117. ISSN1530-891X. PMID29498915.
^Parham, Walter A.; Mehdirad, Ali A.; Biermann, Kurt M.; Fredman, Carey S. (2006). "Hyperkalemia Revisited". Texas Heart Institute Journal. 33 (1). Texas Heart Institute: 40–47. PMC1413606. PMID16572868.
^Yang, Ming; White, Perrin C. (March 9, 2017). "Risk factors for hospitalization of children with congenital adrenal hyperplasia". Clinical Endocrinology. 86 (5). Wiley: 669–673. doi:10.1111/cen.13309. ISSN0300-0664. PMID28192635. S2CID3053051.
^Rushworth, R. Louise; Chrisp, Georgina L.; Dean, Benjamin; Falhammar, Henrik; Torpy, David J. (2017). "Hospitalisation in Children with Adrenal Insufficiency and Hypopituitarism: Is There a Differential Burden between Boys and Girls and between Age Groups?". Hormone Research in Paediatrics. 88 (5). S. Karger AG: 339–346. doi:10.1159/000479370. ISSN1663-2818. PMID28898882. S2CID8842956.
^Lass, Nina; Reinehr, Thomas (2015). "Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone". Hormone Research in Paediatrics. 84 (4). S. Karger AG: 240–247. doi:10.1159/000437305. ISSN1663-2818. PMID26279278. S2CID32377896.